Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 DDI Study of TAK-438 (vonoprazan) with Low-dose Aspirin or NSAIDs in Healthy Male Subjects
jRCT2080223046Phase 2
- Sponsor
- Takeda
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vonoprazan in Peptic ulcer disease (PUD) and gastric mucosal injury (8 arms), sponsored by Takeda. Primary endpoint: Primary pharmacokinetic interaction.
02
Drugs
vonoprazan
03
Conditions
Peptic ulcer disease (PUD)gastric mucosal injury
Beyond the preview
Go deeper on jRCT2080223046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223046.